Natalie Portman Finds Love Again Two Years After Divorce, Expects Third Child with Tanguy Destable

At 44 years ancient, Natalie Portman’s announcement of her third pregnancy has sparked widespread public interest in the medical realities of advanced maternal age. While celebrity news often frames such events as personal triumphs, the underlying clinical landscape reveals significant physiological considerations that merit evidence-based discussion. Entering pregnancy after 40 places individuals in a category associated with increased risks for gestational diabetes, hypertensive disorders, chromosomal abnormalities, and preterm birth—factors that necessitate heightened prenatal surveillance and specialized obstetric care.

Key Clinical Takeaways:

• Women aged 40 and above face a two- to three-fold increased risk of gestational diabetes and preeclampsia compared to those under 35.
• The incidence of fetal chromosomal abnormalities, such as trisomy 21, rises exponentially after age 40, reaching approximately 1 in 100 by age 44.
• Proactive prenatal screening, including non-invasive prenatal testing (NIPT) and detailed anatomy ultrasounds, significantly improves maternal and neonatal outcomes in advanced maternal age pregnancies.

The biological mechanisms underlying these risks are rooted in ovarian aging, which diminishes oocyte quality and increases the likelihood of meiotic errors during fertilization. Concurrently, age-related endothelial dysfunction and reduced vascular adaptability heighten susceptibility to pregnancy-induced hypertension. According to a 2023 cohort study published in The Lancet analyzing over 1.2 million pregnancies in high-income countries, women aged 40–44 experienced a 2.8-fold higher risk of gestational diabetes (adjusted OR 2.8, 95% CI 2.5–3.1) and a 3.1-fold increased risk of preeclampsia (adjusted OR 3.1, 95% CI 2.7–3.6) compared to women aged 25–29. These findings underscore the importance of early risk stratification and multidisciplinary management.

“Advanced maternal age is not a contraindication to pregnancy, but it does require a shift from routine to risk-adapted prenatal care. We now have tools like first-trimester combined screening and cell-free DNA testing that allow us to detect chromosomal anomalies with over 99% sensitivity for trisomy 21, enabling informed decision-making well before term.”

Funding for the Lancet study was provided by the Wellcome Trust and the UK Medical Research Council, ensuring independence from commercial influence. The research utilized national birth registries from Sweden and Norway, offering robust epidemiological validity through near-complete population coverage. Beyond genetic screening, clinicians emphasize cardiovascular monitoring, given that ischemic heart disease remains a leading cause of maternal mortality in older pregnant individuals. A 2022 scientific statement from the American Heart Association, published in Circulation, recommends preconception cardiovascular assessment for women over 40 planning pregnancy, including echocardiography and stress testing when indicated.

“We see too many cases where hypertension or diabetes goes undetected until late in pregnancy because symptoms are attributed to normal gestation. Proactive screening isn’t alarmist—it’s preventive medicine at its most effective.”

For patients navigating pregnancy at an advanced maternal age, establishing care with specialists equipped to manage complex obstetric scenarios is critical. Access to board-certified maternal-fetal medicine specialists ensures timely interpretation of screening results and coordination of care for comorbidities. Similarly, individuals with preexisting cardiac risk factors benefit from consultation with preventive cardiologists who can assess hemodynamic tolerance and guide safe activity levels throughout gestation. Nutritional optimization also plays a pivotal role; registered dietitians with expertise in prenatal metabolism—accessible via prenatal nutrition specialists—can tailor dietary plans to mitigate glycemic excursions and support fetal growth without exacerbating maternal insulin resistance.

The evolving standard of care for advanced maternal age pregnancies reflects a broader trend toward precision obstetrics, integrating genomic screening, biomarker analytics, and individualized risk profiles. While no intervention eliminates all age-related risks, early detection and proactive management significantly reduce morbidity. Future directions include wider implementation of first-trimester placental growth factor (PlGF) testing to predict preeclampsia onset and expanded use of low-dose aspirin prophylaxis, which has demonstrated a 15–20% reduction in preterm preeclampsia when initiated before 16 weeks in high-risk populations.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.